Q & M Dental Group Ltd - Rebound on track

23 Aug 2021
  • 2Q21 PATMI within expectations, at 49% of our adjusted FY21e forecast. Revenue spiked 105% YoY to S$50.8mn. Normalised PATMI was up 10x. 1-for-5 bonus issue and 1 cent quarterly dividend announced.
  • Earnings from Acumen Diagnostics’ COVID-19 PCR tests were an estimated S$3mn, up from S$0.6mn the previous quarter.
  • Maintain BUY. Target price dips to S$0.98 from S$1.00 as we revamp our valuations. We now peg Acumen at S$60mn, at the proposed purchase price by Aoxin for a 49% stake. We roll over our 25x core P/E valuation to FY22e. Another S$0.04 has been added from the market value of listed associate, Aoxin Q & M Dental (S$0.225, Not Rated), at a 20% discount.

 

The Positives

+ Bounce in revenue. Increased demand for dental procedures due to closed borders, PCR test revenue and a higher number of dental clinics led to a 105% YoY surge in revenue. This was aided by a lower base last year due to circuit breaker. Core dental service rose 86% YoY to S$38mn. Medical equipment sales, including PCR tests, tripled to S$12.7mn. Revenue per dental clinic jumped 71% YoY to around S$308k in 2Q21. Pre-pandemic revenue per clinic in 2Q19 was around S$295k, a modest 5% lower. Industry data point to slower dental admissions in May and June 2021, likely due to the Phase 2HA lockdown.

 

+ COVID-19 PCR test earnings spiked. Earnings from PCR tests were around S$3mn this quarter, based on minority interest. This was a jump from S$0.6mn in the previous quarter. No details were disclosed. We model around S$7mn from PCR tests for FY21e.

 

 

The Negative

– New-clinic openings below run rate, for now. Q & M opened seven new clinics in 1H21: four in Singapore and three in Malaysia. This was below our forecast of 25. It plans to open 30 p.a. In Singapore, another six sites have been secured with 10 more to be completed. Singapore  appears on course for 20 new clinics but expansion in Malaysia remains fluid due to the pandemic. Revenue per clinic in Singapore is typically 4x higher than Malaysia.

 

Outlook

We expect dental admissions to remain healthy in 2H21. New clinics are expected to form the foundation of revenue growth in Singapore. Despite a rebound in revenue per clinic, industry patient volumes are still below pre-pandemic levels.

 

We forecast lower PCR testing income for FY22e. As the country moves towards higher vaccination rates and an endemic COVID-19, there is less clarity on the number of tests which will be administered in the next two years. That said, testing should remain an important tool as the country opens its borders. PCR testing will likely be required for vaccinated travellers, unlinked cases and routine tests.

 

Maintain BUY with lower TP of S$0.98, from S$1.00

We keep FY21e earnings unchanged but our valuation metrics has changed (Figure 1). Earlier, Acumen Diagnostics was valued together with group earnings at 25x FY21e PE. We now separately value Acumen. Associate Axoin is proposing to acquire the remaining 49% stake in Acumen for S$29.4mn via the issuance of 127.3mn shares at S$0.231 per share. The vendors are Acumen Holdings and Ong Siew Hwa (Figure 2). Our valuation for Acumen Diagnostics is now pegged to its implied S$60mn valuation.

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com